Harmony Biosciences(NASDAQ) HRMY

Harmony helps patients with rare brain disorders manage daily symptoms. Its main drug helps people with narcolepsy stay awake and alert. The company creates treatments that do not cause drug addiction.

The Sleep and Wake Toolkit

• WAKIX: A once-daily pill for excessive daytime sleepiness and sudden muscle weakness in patients with narcolepsy; this treatment is not a controlled substance.
• Rare Epilepsy Pipeline: Drug candidates such as EPX-100 in Phase 3 testing for Dravet Syndrome and Lennox-Gastaut Syndrome, which are severe forms of epilepsy.
• Next-Generation Pitolisant: New formulas designed to treat idiopathic hypersomnia, a condition causing extreme sleepiness, with clinical data expected in 2027.
• Orexin 2 Agonist: A preclinical compound focused on the brain’s wake-promoting system to treat narcolepsy and other sleep disorders.

Growing Through New Partnerships

• Licensed the exclusive rights to pitolisant from Bioprojet in 2017 to establish its core commercial business.
• Acquired Zynerba Pharmaceuticals in 2023 to expand its portfolio into synthetic cannabinoid treatments for rare conditions.
• Purchased Epygenix Therapeutics in 2024 to enter the pediatric and rare epilepsy market with serotonin-based candidates.
• Expanded its relationship with Bioprojet in 2024 through a sublicense for a new orexin 2 receptor agonist.
• Entered a research collaboration with CiRC Biosciences in 2025 to develop cell replacement therapies for refractory epilepsy and narcolepsy.

Why This Approach Works

Harmony focuses on the H3 receptor, a brain signal that regulates wakefulness and inhibits sleep. This strategy allows the company to offer narcolepsy treatments that avoid the legal restrictions and abuse risks associated with traditional stimulants.

The Latest Financial Results

• Revenue was $243.8 million in Q4 2025, up 21.1% from Q4 2024.
• Gross profit reached $175.2 million in Q4 2025, up 19.3% year-over-year.
• Operating income was $38.6 million in Q4 2025, down 30.8% from the previous year.
• Free cash flow hit $126 million in Q4 2025, up 67.9% from Q4 2024.
• Operating cash flow rose to $126.2 million in Q4 2025, up 67% from the same period in 2024.

Bottom Line

Harmony has transformed from a single-product company into a diversified neuroscience specialist. Its shift into rare epilepsy and next-generation sleep formulas has significantly expanded its clinical pipeline beyond its original focus.